Artigos de Perspetiva
Cardio-Oncology: To Enable Cancer Treatment while Minimizing Cardiovascular Toxicity
Conteúdo principal do artigo
Andreia Magalhães
Detalhes do artigo
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Referências
Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J.2022;43:4229-361.6. doi: 10.1093/eurheartj/ehac244.
Nobre Menezes M, Tavares da Silva M, Magalhães A, Melica B, Toste JC, Calé R, et al. Interventional cardiology in cancer patients: A position paper from the Portuguese Cardiovascular Intervention Association and the Portuguese Cardio-Oncology Study Group of the Portuguese Society of Cardiology. Rev Port Cardiol. 2023S0870-2551(23)00382-7. doi: 10.1016/j.repc.2023.04.013.
Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Electronic address: clinicalguidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31:171-90. doi: 10.1016/j.annonc.2019.10.023.
Bell CF, Lei X, Haas A, Baylis RA, Gao H, Luo L, et al. Risk of Cancer After Diagnosis of Cardiovascular Disease. JACC CardioOncol. 2023;5:431-40. doi: 10.1016/j.jaccao.2023.01.010.
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377:111-21. doi: 10.1056/NEJMoa1701719.
